BioInvent International

Lund, Sweden – December 18, 2025 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that representatives from the Company management team will participate in the following upcoming investor conferences this January:

J.P. Morgan 2026 Healthcare Conference, San Francisco, US
Format: One-on-one meetings
Date: January 12-14

15th Annual LifeSci Partners Corporate Access Event, San Francisco, US
Format: One-on-one meetings
Date: January 12-13

Sweden Networking Breakfast at J.P. Morgan 2026, San Francisco, US
Format: Panel Discussion
Date and Time: January 12, 7:30 am PT

Redeye Fight Cancer event 2026, Stockholm, Sweden
Format: Presentation and Q&A
Date: January 21, 2026

About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.

For further information, please contact:
Cecilia Hofvander, VP Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com

BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com